Similarly, statins, fatty acid synthase (FASN) inhibitors, and neutral sphingomyelinase 2 (nSMase2) inhibitors—primarily used for treating cancer or metabolic diseases [174,175,176]—are receiving significant attention for their potential to inhibit viral release by altering membrane lipid composition, though their clinical application as antiviral therapies requires further validation. Here, FASN is linked to cancer.